Author - Sydney Stewart

iRhythm Technologies

WB starts iRhythm Technologies at OP

William Blair launched coverage of iRhythm Technologies (NASDAQ:IRTC) with an “outperform” rating, calling the company’s digital health platform “market disrupting.” The stock closed at $71.76, up $1.12, on Jan. 9...

iBio Inc.

iBio initiates new litigation against Fraunhofer

iBio (NYSE AMERICAN:IBIO) filed a motion in the Court of Chancery of the State of Delaware to initiate new litigation against Fraunhofer-Gesellschaft through an amended complaint. The new motion asserts that depositions...

BTIG cuts Valeritas Holdings to neutral; removes PT

BTIG downgraded Valeritas Holdings (NASDAQ:VLRX) to “neutral” from “buy” and removed its previous $10 price target after the company reduced its fourth quarter revenue guidance due to a temporary supply disruption and...

X4 Pharma

Roth starts X4 Pharma at buy; PT $20

Roth Capital Partners launched coverage of X4 Pharmaceuticals (NASDAQ:XFOR) with a “buy” rating and $20 price target. The stock closed at $11 on Dec. 17. Analyst Zegbeh Jallah writes that her investment thesis is based...

Adamas Pharmaceuticals

SVB Leerink halves Adamas Pharma PT to $6

SVB Leerink lowered its price target for Adamas Pharmaceuticals (NASDAQ:ADMS) to $6 from $13, saying the mixed Phase 3 INROADS data are not good enough. In afternoon trading on Dec. 17, the stock was quoted at $4.15...


Sign up to our weekly BioTuesdays newsletter.